Unasyn (Ampicillin-Sulbactam): Clinical Overview
Unasyn is NOT recommended as empiric therapy for community-acquired intra-abdominal infections due to high rates of E. coli resistance, but remains useful for specific indications including β-lactamase-producing enterococcal endocarditis, HACEK endocarditis, selected skin/soft tissue infections, and as an alternative for community-acquired pneumonia. 1
Contraindications
Unasyn is absolutely contraindicated in patients with:
- History of serious hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) to ampicillin, sulbactam, or other β-lactams
- Previous cholestatic jaundice or hepatic dysfunction associated with Unasyn 2
Primary Indications
Endocarditis
For β-lactamase-producing enterococcal endocarditis: Ampicillin-sulbactam 12 g/24h IV divided every 6 hours for 6 weeks, combined with gentamicin 3 mg/kg/24h IV/IM divided every 8 hours 3. This represents a Class IIa recommendation for strains resistant to penicillin but susceptible to aminoglycosides and vancomycin.
For HACEK organism endocarditis: Ampicillin-sulbactam 12 g/24h IV divided every 6 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve) 4. Pediatric dosing: 300 mg/kg/24h IV divided every 4-6 hours.
Community-Acquired Pneumonia (Hospitalized Patients)
Ampicillin-sulbactam 1.5-3 g every 6 hours combined with a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) is a strong recommendation for hospitalized adults without MRSA or Pseudomonas risk factors 5. This represents a first-line option alongside fluoroquinolone monotherapy.
Skin and Soft Tissue Infections
For surgical site infections involving the axilla or perineum, ampicillin-sulbactam 3 g every 6 hours IV is appropriate empiric therapy 6. For necrotizing infections, use ampicillin-sulbactam 3 g every 6 hours plus gentamicin 5 mg/kg every 24 hours IV as part of broad empiric coverage.
Culture-Negative Endocarditis
For native valve culture-negative endocarditis: Ampicillin-sulbactam 12 g/24h IV in 4 divided doses plus gentamicin 3 mg/kg/24h IV/IM in 3 divided doses for 4-6 weeks 4. Consultation with infectious diseases is mandatory.
Critical Limitation: Intra-Abdominal Infections
Ampicillin-sulbactam is explicitly NOT recommended for community-acquired intra-abdominal infections due to high rates of E. coli resistance 1. This is a B-II strength recommendation from the 2010 IDSA/SIS guidelines. The guideline specifically states to avoid this agent in favor of alternatives like ticarcillin-clavulanate, ertapenem, or combination regimens with better gram-negative coverage.
This represents a significant departure from older practice patterns. While the 2003 guidelines listed ampicillin-sulbactam as an option for mild-to-moderate community-acquired intra-abdominal infections 7, the 2010 update removed this recommendation based on emerging resistance data.
Dosing Recommendations
Adults (Normal Renal Function)
- Standard dosing: 1.5-3 g IV every 6 hours
- High-dose regimen: 12 g/24h IV divided every 6 hours (for endocarditis)
- Infusion: Can be given as 15-minute infusion or continuous infusion 8
Pediatric Dosing
- Infants: 100-150 mg ampicillin/kg/day divided every 6 hours 9
- Children: 100-200 mg ampicillin/kg/day divided every 6 hours 9
- Endocarditis: 300 mg/kg/24h IV divided every 4 hours 3, 10
Renal Adjustment
Significant dose reduction required with renal impairment. Drug accumulation occurs with decreased GFR, particularly affecting sulbactam clearance 8. Therapeutic drug monitoring should be considered in critically ill patients with acute kidney injury, as concentrations can be 2-fold higher than in patients with normal renal function.
Stability and Preparation
After reconstitution 2:
- Sterile water/0.9% NaCl: Stable 8 hours at 25°C, 48 hours at 4°C (at 45 mg/mL concentration)
- 5% Dextrose: Stable only 2 hours at 25°C (at 30 mg/mL concentration)
- Maximum concentration: 45 mg/mL (30 mg ampicillin + 15 mg sulbactam per mL)
For IM use, reconstitute with sterile water, 0.5% lidocaine, or 2% lidocaine to achieve 375 mg/mL. Use within 1 hour of preparation.
Special Considerations
Acinetobacter baumannii
Sulbactam has intrinsic activity against Acinetobacter baumannii, making ampicillin-sulbactam valuable for carbapenem-resistant strains 11, 12. High-dose extended infusion (3 g every 8 hours as 4-hour infusion) may be required for isolates with MIC 8 mg/L. However, efficacy is limited against strains resistant to both sulbactam and meropenem.
Continuous Infusion
Continuous infusion of 8 g ampicillin/4 g sulbactam per 24 hours (after 2/1 g loading dose) maintains concentrations above MIC breakpoints in critically ill patients 8. This approach achieves 100% probability of target attainment for MIC ≤8 mg/L, though concentrations can be subtherapeutic with augmented renal clearance.
Common Pitfalls
- Do not use for empiric intra-abdominal infections - resistance rates are too high 1
- Avoid in Bacteroides fragilis infections - increasing resistance documented 1
- Not active against Pseudomonas aeruginosa - never use when this pathogen is suspected 11
- Pain at injection site is the most common adverse effect with IM administration 13
- Diarrhea is the most common systemic adverse effect 11